Belén Ocaña-Paredes, Sebastián Rivera-Orellana, David Ramírez-Sánchez, Juliana Montalvo-Guerrero, María Paula Freire, Samantha Espinoza-Ferrao, Adriana Altamirano-Colina, Paulina Echeverría-Espinoza, María José Ramos-Medina, Gabriela Echeverría-Garcés, Danilo Granda-Moncayo, Andrea Jácome-Alvarado, María Gabriela Andrade, Andrés López-Cortés
Epigenetic modifications, characterized by changes in gene expression without altering the DNA sequence, play a crucial role in the development and progression of cancer by significantly influencing gene activity and cellular function. This insight has led to the development of a novel class of therapeutic agents, known as epigenetic drugs. These drugs, including histone deacetylase inhibitors, histone acetyltransferase inhibitors, histone methyltransferase inhibitors, and DNA methyltransferase inhibitors, aim to modulate gene expression to curb cancer growth by uniquely altering the epigenetic landscape of cancer cells...
2024: Frontiers in Pharmacology